KRAS and pancreatic neoplasm: Given that a K-Ras mutation is a key mechanism of pancreatic carcinogenesis, we hypothesized that treatment of MEK inhibitors could interrupt the K-Ras downstream signaling pathway to reduce the survival of pancreatic cancer cells.